Table 3 Cox proportional hazards analysis of time to first AIDS event following initiation of HAART by period of HAART initiation
Variable | Unadjusted Hazard Ratio (95% CI) | p-value | Adjusted Hazard Ratio (95% CI) | p-value | Adjusted Hazard Ratio (95% CI) | p-value |
|---|---|---|---|---|---|---|
w/adherence | w/o adherence | |||||
Age (per decade) | 1.16 (1.01-1.32) | 0.031 | 1.18 (1.03-1.35) | 0.020 | ||
Gender | 0.133 | |||||
Female | 1.00 | |||||
Male | 1.33 (0.92-1.94) | |||||
Baseline AIDS defining illness | 1.93 (1.42-2.63) | < 0.001 | ||||
CD4 (per 100 cells) | 0.64 (0.57-0.72) | < 0.001 | ||||
Baseline CD4 | ||||||
< 50 | 4.76 (3.38-6.70) | < 0.001 | 3.56 (2.48-5.11) | < 0.001 | 3.48 (2.43-4.99) | < 0.001 |
50-199 | 1.93 (1.37-2.70) | < 0.001 | 1.61 (1.14-2.28) | 1.60 (1.13-2.26) | 0.008 | |
200+ | 1.00 | 1.00 | 0.007 | 1.00 | ||
Baseline Viral Load (log10) | 3.32 (1.99-5.54) | < 0.001 | 2.07 (1.50-2.85) | < 0.001 | 2.03 (1.47-2.79) | < 0.001 |
Baseline Viral Load | < 0.001 | |||||
< 100,000 | 1.00 | |||||
> 100,000 | 2.67 (1.96-3.64) | |||||
Third drug of baseline therapy | 0.003 | 0.073 | 0.096 | |||
PI | 1.00 | 1.00 | 1.00 | |||
NNRTI | 0.64 (0.47-0.86) | 0.75 (0.55-1.03) | 0.77 (0.56-1.05) | |||
Hepatitis C | 0.595 | |||||
Negative | 1.00 | 0.560 | ||||
Positive | 1.08 (0.81-1.43) | |||||
unknown | 1.15 (0.73-1.81) | |||||
History of Injection drug use | 1.12 (0.85-1.46) | 0.424 | ||||
Year therapy started (per year increase) | 1.03 (0.99-1.07) | 0.189 | ||||
ERA therapy started | ||||||
96-98 | 1.00 | 1.00 | 1.00 | |||
99-01 | 1.25 (0.83-1.87) | 0.286 | 1.25 (0.82-1.91) | 0.293 | 1.24 (0.81-1.88) | 0.320 |
02-04 | 1.77 (1.20-2.60) | 0.004 | 1.59 (1.06-2.39) | 0.025 | 1.55 (1.04-2.32) | 0.032 |
05-07 | 1.26 (0.85-1.86) | 0.251 | 1.36 (0.90-2.04) | 0.141 | 1.26 (0.85-1.88) | 0.255 |
One-year Adherence (per 10% increase) | 0.89 (0.86-0.93) | < 0.001 | ||||
One-year Adherence | < 0.001 | < 0.001 | ||||
< 95% | 1.00 | 1.00 | ||||
≥ 95% | 0.50 (0.38-0.65) | 0.42 (0.32-0.56) |